



## **About Fedora Pharmaceuticals Inc.**

Founded in 2011, Fedora Pharmaceuticals is privately-held and is headquartered in Edmonton, Alberta, Canada. Fedora has a rich pipeline of antibiotic candidates. Nacubactam is Fedora's most advanced product and is a beta-lactamase inhibitor. Beta-Lactamases are enzymes that destroy beta-lactam antibiotics, such as penicillins, cephalosporins, and carbapenems (which account for over 60% of all antibiotics prescribed) rendering them ineffective. Nacubactam selectively and effectively inhibits beta-lactamases and hence, return the activity of the antibiotics. Nacubactam has completed several phase 1 clinical trials and is available for licensing as a combination product with meropenem.

Additionally, Fedora Pharmaceuticals is developing a series of earlier and mid-stage antibiotic candidates with the goal of selecting one or more candidates to advance into clinical trials by 2022. Fedora's management and scientific team of staff and collaborators bring a wealth of knowledge and expertise in drug discovery and development to the challenge of antimicrobial drug development. Together, they have led the discovery and development of an extensive list of anti-infectives, many of which are in clinical use today.

### **Business Objectives:**

- Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial agents to address the ever-rising threat of antimicrobial resistance (AMR).

## **Contact**

### **Sameeh M. Salama, Ph.D.**

Chief Scientific Officer  
Fedora Pharmaceuticals Inc.  
Tel: (780) 761 0562  
sameeh@fedorapharma.com

Fedora Pharmaceuticals Inc.  
11629 105 Avenue  
Edmonton, AB. Canada  
T5H 0L9, 780.705.0575  
www.brassdomeventures.com